Edwards Lifesciences (EW) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Edwards Lifesciences Revenue Highlights

Latest Revenue (Y)

$5.44B

Latest Revenue (Q)

$1.35B

Main Segment (Y)

Transcatheter Heart Valves

Main Geography (Y)

UNITED STATES

Edwards Lifesciences Revenue by Period

Edwards Lifesciences Revenue by Year

Date	Revenue	Change
2024-12-31	$5.44B	-9.41%
2023-12-31	$6.00B	11.56%
2022-12-31	$5.38B	2.86%
2021-12-31	$5.23B	19.29%
2020-12-31	$4.39B	0.88%
2019-12-31	$4.35B	16.79%
2018-12-31	$3.72B	8.37%
2017-12-31	$3.44B	15.91%
2016-12-31	$2.96B	18.85%
2015-12-31	$2.49B	7.35%
2014-12-31	$2.32B	13.56%
2013-12-31	$2.05B	7.68%
2012-12-31	$1.90B	13.17%
2011-12-31	$1.68B	16.01%
2010-12-31	$1.45B	9.51%
2009-12-31	$1.32B	6.76%
2008-12-31	$1.24B	13.44%
2007-12-31	$1.09B	5.22%
2006-12-31	$1.04B	3.92%
2005-12-31	$997.90M	7.13%
2004-12-31	$931.50M	8.25%
2003-12-31	$860.50M	22.23%
2002-12-31	$704.00M	1.73%
2001-12-31	$692.00M	-13.93%
2000-12-31	$804.00M	-11.16%
1999-12-31	$905.00M	-

Edwards Lifesciences generated $5.44B in revenue during NA 2024, up -9.41% compared to the previous quarter, and up 125.10% compared to the same period a year ago.

Edwards Lifesciences Revenue by Quarter

Date	Revenue	Change
2024-09-30	$1.35B	-2.27%
2024-06-30	$1.39B	-13.28%
2024-03-31	$1.60B	4.18%
2023-12-31	$1.53B	3.59%
2023-09-30	$1.48B	-3.22%
2023-06-30	$1.53B	4.84%
2023-03-31	$1.46B	8.25%
2022-12-31	$1.35B	2.22%
2022-09-30	$1.32B	-4.00%
2022-06-30	$1.37B	2.44%
2022-03-31	$1.34B	0.86%
2021-12-31	$1.33B	1.49%
2021-09-30	$1.31B	-4.78%
2021-06-30	$1.38B	13.10%
2021-03-31	$1.22B	2.09%
2020-12-31	$1.19B	4.45%
2020-09-30	$1.14B	23.34%
2020-06-30	$925.00M	-18.05%
2020-03-31	$1.13B	-3.87%
2019-12-31	$1.17B	7.32%
2019-09-30	$1.09B	0.65%
2019-06-30	$1.09B	9.46%
2019-03-31	$993.00M	1.56%
2018-12-31	$977.70M	7.84%
2018-09-30	$906.60M	-3.93%
2018-06-30	$943.70M	5.46%
2018-03-31	$894.80M	0.71%
2017-12-31	$888.50M	8.16%
2017-09-30	$821.50M	-2.41%
2017-06-30	$841.80M	-4.72%
2017-03-31	$883.50M	15.08%
2016-12-31	$767.70M	3.83%
2016-09-30	$739.40M	-2.62%
2016-06-30	$759.30M	8.89%
2016-03-31	$697.30M	3.90%
2015-12-31	$671.10M	9.03%
2015-09-30	$615.50M	-0.21%
2015-06-30	$616.80M	4.49%
2015-03-31	$590.30M	-4.48%
2014-12-31	$618.00M	1.75%
2014-09-30	$607.40M	5.62%
2014-06-30	$575.10M	10.09%
2014-03-31	$522.40M	-2.54%
2013-12-31	$536.00M	8.15%
2013-09-30	$495.60M	-4.18%
2013-06-30	$517.20M	4.13%
2013-03-31	$496.70M	-2.70%
2012-12-31	$510.50M	13.98%
2012-09-30	$447.90M	-7.07%
2012-06-30	$482.00M	4.97%
2012-03-31	$459.20M	6.74%
2011-12-31	$430.20M	4.24%
2011-09-30	$412.70M	-4.29%
2011-06-30	$431.20M	6.60%
2011-03-31	$404.50M	3.08%
2010-12-31	$392.40M	12.47%
2010-09-30	$348.90M	-4.46%
2010-06-30	$365.20M	7.25%
2010-03-31	$340.50M	-1.79%
2009-12-31	$346.70M	6.45%
2009-09-30	$325.70M	-2.92%
2009-06-30	$335.50M	7.02%
2009-03-31	$313.50M	1.23%
2008-12-31	$309.70M	2.01%
2008-09-30	$303.60M	-7.33%
2008-06-30	$327.60M	10.38%
2008-03-31	$296.80M	-

Edwards Lifesciences generated $1.35B in revenue during Q3 2024, up -2.27% compared to the previous quarter, and up 88.51% compared to the same period a year ago.

Edwards Lifesciences Revenue Breakdown

Edwards Lifesciences Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Surgical Heart Valve Therapy	$981.30M	$999.30M	$893.10M	$889.10M	$761.80M
Transcatheter Heart Valves	$4.11B	$3.88B	-	-	-
Transcatheter Mitral And Tricuspid Therapies	$352.10M	$197.60M	$116.10M	$86.00M	$41.80M
Critical Care	-	$928.10M	$855.00M	$834.90M	$725.40M
Transcatheter Aortic Valve Replacement	-	$3.88B	$3.52B	$3.42B	$2.86B

Edwards Lifesciences's latest annual revenue breakdown by segment (product or service), as of Dec 24: Transcatheter Heart Valves (75.49%), Surgical Heart Valve Therapy (18.04%), and Transcatheter Mitral And Tricuspid Therapies (6.47%).

Quarterly Revenue by Product

Product/Service	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20
Transcatheter Heart Valves	$1.04B	$1.02B	$1.04B	$1.01B	$979.40M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Transcatheter Mitral And Tricuspid Therapies	$105.10M	$91.10M	$83.00M	$72.90M	$56.00M	$52.40M	$47.60M	$41.60M	$31.50M	$29.70M	$27.90M	$27.00M	$25.30M	$22.30M	$22.10M	$16.30M	$13.10M	$12.10M	$6.10M	$10.50M
Surgical Heart Valve Therapy	$210.90M	$240.00M	$264.30M	$266.10M	$248.20M	$246.60M	$256.30M	$248.20M	$224.10M	$219.70M	$228.50M	$220.80M	$221.30M	$217.40M	$237.40M	$213.00M	$204.20M	$203.30M	$160.90M	$193.40M
Critical Care	-	-	-	$251.30M	$250.50M	$221.00M	$234.70M	$221.90M	$225.00M	$207.30M	$210.60M	$212.10M	$211.60M	$212.70M	$215.00M	$195.60M	$198.20M	$180.90M	$163.70M	$182.60M
Transcatheter Aortic Valve Replacement	-	-	-	-	$979.40M	$960.90M	$991.60M	$947.90M	$867.70M	$862.30M	$906.90M	$881.30M	$871.50M	$857.80M	$901.50M	$791.70M	$776.20M	$744.60M	$594.30M	$742.20M

Edwards Lifesciences's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Transcatheter Heart Valves (76.63%), Surgical Heart Valve Therapy (15.60%), and Transcatheter Mitral And Tricuspid Therapies (7.77%).

Edwards Lifesciences Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
JAPAN	$339.80M	$452.40M	$473.60M	$528.90M	$460.10M
Europe	$1.32B	$1.33B	$1.17B	$1.19B	$973.60M
UNITED STATES	$3.21B	$3.51B	$3.13B	$2.96B	$2.52B
Rest of World	$572.00M	$709.20M	$601.40M	$550.20M	$435.80M

Edwards Lifesciences's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (58.94%), Europe (24.30%), Rest of World (10.52%), and JAPAN (6.25%).

Quarterly Revenue by Country

Country	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20
UNITED STATES	$643.90M	$804.60M	$816.80M	$940.70M	$894.40M	$869.90M	$895.30M	$849.10M	$795.50M	$786.80M	$800.80M	$749.50M	$739.50M	$753.20M	$795.70M	$674.70M	$671.20M	$662.00M	$516.20M	$667.40M
Europe	$298.50M	$319.80M	$335.60M	$367.80M	$344.90M	$322.30M	$336.20M	$331.10M	$290.80M	$270.10M	$302.80M	$311.10M	$309.40M	$291.10M	$309.80M	$280.00M	$265.80M	$253.80M	$204.70M	$249.30M
JAPAN	$60.20M	$81.40M	$87.40M	$110.80M	$112.00M	$108.40M	$117.90M	$114.10M	$111.10M	$104.10M	$122.90M	$135.50M	$138.90M	$125.90M	$131.80M	$132.30M	$129.40M	$113.90M	$106.80M	$110.00M
Rest of World	$98.40M	$148.60M	$146.10M	$178.90M	$182.80M	$180.30M	$180.80M	$165.30M	$150.90M	$158.00M	$147.40M	$145.10M	$141.90M	$140.00M	$138.70M	$129.60M	$125.30M	$111.20M	$97.30M	$102.00M

Edwards Lifesciences's latest quarterly revenue breakdown by geography, as of Dec 24: UNITED STATES (58.48%), Europe (27.11%), Rest of World (8.94%), and JAPAN (5.47%).

Edwards Lifesciences Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
ABT	Abbott Laboratories	$41.95B	$10.63B
MDT	Medtronic	$32.36B	$8.29B
SYK	Stryker	$22.59B	$5.49B
BSX	Boston Scientific	$16.75B	$3.39B
EW	Edwards Lifesciences	$5.44B	$1.35B
ALGN	Align	$4.00B	$977.87M
DXCM	DexCom	$3.62B	$994.20M
PODD	Insulet	$2.07B	$372.60M
ZBH	Zimmer Biomet	$2.02B	$143.40M
TNDM	Tandem Diabetes Care	$940.20M	$363.29M

EW Revenue FAQ

What is Edwards Lifesciences’s yearly revenue?

Edwards Lifesciences's yearly revenue for 2024 was $5.44B, representing a decrease of -9.41% compared to 2023. The company's yearly revenue for 2023 was $6B, representing an increase of 11.56% compared to 2022. EW's yearly revenue for 2022 was $5.38B, representing an increase of 2.86% compared to 2021.

What is Edwards Lifesciences’s quarterly revenue?

Edwards Lifesciences's quarterly revenue for Q3 2024 was $1.35B, a -2.27% decrease from the previous quarter (Q2 2024), and a -8.54% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $1.39B, a -13.28% decrease from the previous quarter (Q1 2024), and a -9.43% decrease year-over-year (Q2 2023). EW's quarterly revenue for Q1 2024 was $1.6B, a 4.18% increase from the previous quarter (Q4 2023), and a 9.50% increase year-over-year (Q1 2023).

What is Edwards Lifesciences’s revenue growth rate?

Edwards Lifesciences's revenue growth rate for the last 3 years (2022-2024) was 1.06%, and for the last 5 years (2020-2024) was 24.01%.

What are Edwards Lifesciences’s revenue streams?

Edwards Lifesciences's revenue streams in c 24 are Surgical Heart Valve Therapy, Transcatheter Heart Valves, and Transcatheter Mitral And Tricuspid Therapies. Surgical Heart Valve Therapy generated $981.3M in revenue, accounting 18.04% of the company's total revenue, down -1.80% year-over-year. Transcatheter Heart Valves generated $4.11B in revenue, accounting 75.49% of the company's total revenue, up 5.83% year-over-year. Transcatheter Mitral And Tricuspid Therapies generated $352.1M in revenue, accounting 6.47% of the company's total revenue, up 78.19% year-over-year.

What is Edwards Lifesciences’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Edwards Lifesciences was Transcatheter Heart Valves. This segment made a revenue of $4.11B, representing 75.49% of the company's total revenue.